199522-60-6

Upstream product

• 109-04-6 2-bromo-pyridine 
• 38585-73-8 N-(2-pyridinyl)-1,3-propandiamine 
• 195053-88-4 2-[3-(1-trityl-1H-imidazol-4-yl)propyl]isoindoline-1,3-dione 
• 31434-93-2 methyl 3-(4-imidazolyl)propionate 
• 76-83-5 trityl chloride 
• 199522-62-8 3-propyl isothiocyanate 
• 195053-89-5 4-(3-aminopropyl)-1-(triphenylmethyl)-imidazole 
• 199522-61-7 N₁-(4-bromobenzyl)-N₁-(pyridin-2-yl)-propane-1,3-diamine 
• 152030-49-4 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol 
• 102676-60-8 3-(1-triphenylmethyl-1H-imidazol-4-yl)propanoic acid methyl ester 

Relevant academic research and scientific papers

USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE

The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of general formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions being high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.

Somatostatin agonists and antagonists

The present invention relates to compounds, compositions containing them, and their use for treating medical disorders related to binding to human somatostatin receptor subtypes.

Use of somatostatin agonists and antagonists for treating diseases related to the eye

The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of the general formula Ia or Ib or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4 and, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions are high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.

Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity

The discovery of novel non-peptide compounds with a high affinity for the peptide hormone somatostatin (SST) receptor is described. The compounds were tested for affinity at five human SST receptor subtypes individually expressed in mammalian cells. The c